Article Versions Notes

Yeh J-H, Tsai H-L, Chen Y-C, Li C-C, Huang C-W, Chang T-K, Su W-C, Chen P-J, Liu Y-P, Wang J-Y. BRAF, MEK, and EGFR Triplet Inhibitors as Salvage Therapy in BRAF-Mutated Metastatic Colorectal Cancer—A Case Series Study Target Therapy of BRAF-Mutated mCRC. Medicina. 2021; 57(12):1339. https://doi.org/10.3390/medicina57121339

Yeh, Jen-Hao, Hsiang-Lin Tsai, Yen-Cheng Chen, Ching-Chun Li, Ching-Wen Huang, Tsung-Kun Chang, Wei-Chih Su, Po-Jung Chen, Yu-Peng Liu, and Jaw-Yuan Wang. 2021. "BRAF, MEK, and EGFR Triplet Inhibitors as Salvage Therapy in BRAF-Mutated Metastatic Colorectal Cancer—A Case Series Study Target Therapy of BRAF-Mutated mCRC" Medicina 57, no. 12: 1339. https://doi.org/10.3390/medicina57121339

Yeh, J.-H., Tsai, H.-L., Chen, Y.-C., Li, C.-C., Huang, C.-W., Chang, T.-K., Su, W.-C., Chen, P.-J., Liu, Y.-P., & Wang, J.-Y. (2021). BRAF, MEK, and EGFR Triplet Inhibitors as Salvage Therapy in BRAF-Mutated Metastatic Colorectal Cancer—A Case Series Study Target Therapy of BRAF-Mutated mCRC. Medicina, 57(12), 1339. https://doi.org/10.3390/medicina57121339